Nasser M. Alorfi

Mecca, 21955, Saudi Arabia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications

pH-Responsive Carboxymethyl Cellulose-Encapsulating Hesperidin-Selenium Nanoparticles Attenuate Paracetamol-Induced Acute Kidney Injury via Keap-1/Nrf2, NF-κB, and Mitochondrial Apoptosis Modulation.

pH-Responsive Carboxymethyl Cellulose-Encapsulating Hesperidin-Selenium Nanoparticles Attenuate Paracetamol-Induced Acute Kidney Injury via Keap-1/Nrf2, NF-κB, and Mitochondrial Apoptosis Modulation.

Journal: International journal of molecular sciences
Published: July 04, 2026

Patient Attitudes and Factors Associated with Willingness to Deprescribe Prescribed Medications in Western Saudi Arabia: A Cross-Sectional Study.

Patient Attitudes and Factors Associated with Willingness to Deprescribe Prescribed Medications in Western Saudi Arabia: A Cross-Sectional Study.

Journal: Healthcare (Basel, Switzerland)
Published: June 01, 2026

Global pharmacovigilance overview of adverse drug reactions associated with propofol: A descriptive pharmacovigilance study using WHO-VigiAccess data.

Global pharmacovigilance overview of adverse drug reactions associated with propofol: A descriptive pharmacovigilance study using WHO-VigiAccess data.

Journal: Medicine
Published: April 07, 2026

Assessing community pharmacists' understanding, attitudes, self-confidence, and obstacles in patient-centered communication.

Assessing community pharmacists' understanding, attitudes, self-confidence, and obstacles in patient-centered communication.

Journal: Future science OA
Published: January 30, 2026

Pharmacological Interventions in the Management of Sports Injuries: A Review of Clinical Use, Dosage Forms, and Anti-Doping Considerations.

Pharmacological Interventions in the Management of Sports Injuries: A Review of Clinical Use, Dosage Forms, and Anti-Doping Considerations.

Journal: Drug design, development and therapy
Published: December 10, 2025

Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials.

Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials.

Journal: Frontiers in medicine
Published: December 10, 2025

GLP-1 Receptor Agonist Therapy in Older Adults with Diabetes: A Qualitative Analysis of Phase 4 ClinicalTrials.gov Studies.

GLP-1 Receptor Agonist Therapy in Older Adults with Diabetes: A Qualitative Analysis of Phase 4 ClinicalTrials.gov Studies.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: November 28, 2025

Pregabalin-associated adverse drug reactions: A real-world pharmacovigilance study using WHO-VigiAccess.

Pregabalin-associated adverse drug reactions: A real-world pharmacovigilance study using WHO-VigiAccess.

Journal: Medicine
Published: November 11, 2025

Pharmacological and device-based interventions for paraplegia: A ClinicalTrials.gov-based analysis.

Pharmacological and device-based interventions for paraplegia: A ClinicalTrials.gov-based analysis.

Journal: Medicine
Published: November 01, 2025

Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports.

Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports.

Journal: Medicine
Published: October 22, 2025

Exploring the Use of GLP-1-Based Interventions for Obesity: A Qualitative Analysis of ClinicalTrials.gov Data.

Exploring the Use of GLP-1-Based Interventions for Obesity: A Qualitative Analysis of ClinicalTrials.gov Data.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: October 21, 2025

Global trends and gaps in pharmacogenetic clinical trials: A cross-sectional analysis of ClinicalTrials.gov registrations.

Global trends and gaps in pharmacogenetic clinical trials: A cross-sectional analysis of ClinicalTrials.gov registrations.

Journal: Medicine
Published: October 07, 2025
Showing 1-12 of 63

Last Updated: 09/26/2026